Thomas F. Ryan Jr - Mar 1, 2022 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Director
Signature
/s/ Kimberly Brown (Attorney in Fact)
Stock symbol
RGEN
Transactions as of
Mar 1, 2022
Transactions value $
-$357,300
Form type
4
Date filed
3/2/2022, 08:14 PM
Previous filing
Nov 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Options Exercise $38.8K +1K +40.7% $38.76* 3.46K Mar 1, 2022 Direct F1
transaction RGEN Common Stock Sale -$198K -1K -28.93% $198.48 2.46K Mar 1, 2022 Direct F2
transaction RGEN Common Stock Sale -$198K -1K -40.7% $197.58 1.46K Mar 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Options Exercise $0 +1K $0.00* 0 Mar 1, 2022 Common Stock 1K $38.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The total reported in Column 5 has been adjusted to correct an overstatement of total holdings by 9,880 shares, first reflected in a Form 4 filed on November 2, 2021.
F2 $198.48 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.19 to $198.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 This option is currently exercisable.